DE69600399T2 - Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung - Google Patents

Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung

Info

Publication number
DE69600399T2
DE69600399T2 DE69600399T DE69600399T DE69600399T2 DE 69600399 T2 DE69600399 T2 DE 69600399T2 DE 69600399 T DE69600399 T DE 69600399T DE 69600399 T DE69600399 T DE 69600399T DE 69600399 T2 DE69600399 T2 DE 69600399T2
Authority
DE
Germany
Prior art keywords
treatment
cgrp antagonist
skin erythema
received
neurogenic origin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69600399T
Other languages
English (en)
Other versions
DE69600399T3 (de
DE69600399D1 (de
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477498&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69600399(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of DE69600399D1 publication Critical patent/DE69600399D1/de
Publication of DE69600399T2 publication Critical patent/DE69600399T2/de
Publication of DE69600399T3 publication Critical patent/DE69600399T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69600399T 1995-03-28 1996-03-04 Verwendung eines Antagonisten von CGRP für die Behandlung von Hautrötungen neurogenen Ursprungs und erhaltene Zusammensetzung Expired - Lifetime DE69600399T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503628 1995-03-28
FR9503628A FR2732221B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue

Publications (3)

Publication Number Publication Date
DE69600399D1 DE69600399D1 (de) 1998-08-13
DE69600399T2 true DE69600399T2 (de) 1998-10-29
DE69600399T3 DE69600399T3 (de) 2005-07-14

Family

ID=9477498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69600399T Expired - Lifetime DE69600399T3 (de) 1995-03-28 1996-03-04 Verwendung eines Antagonisten von CGRP für die Behandlung von Hautrötungen neurogenen Ursprungs und erhaltene Zusammensetzung

Country Status (15)

Country Link
US (2) US5932215A (de)
EP (1) EP0734729B2 (de)
JP (1) JPH08268874A (de)
AR (1) AR002974A1 (de)
AT (1) ATE168011T1 (de)
BR (1) BR9601478A (de)
CA (1) CA2172777C (de)
DE (1) DE69600399T3 (de)
DK (1) DK0734729T4 (de)
ES (1) ES2121461T5 (de)
FR (1) FR2732221B1 (de)
HU (1) HUP9600765A3 (de)
MX (1) MX9601150A (de)
PL (1) PL313515A1 (de)
RU (1) RU2152798C1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
FR2768621B1 (fr) * 1997-09-22 2000-04-07 Oreal Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
CA2301336A1 (en) * 2000-03-17 2001-09-17 Michael T. Kelly Topical treatment of rosacea
WO2002089743A2 (en) * 2001-05-09 2002-11-14 The Regents Of The University Of Michigan Use of compositions for treating rosacea
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US11517612B2 (en) 2016-11-18 2022-12-06 Nepsone Ehf Methods of treating inflammatory skin disorders
RS52750B (sr) 2002-08-12 2013-08-30 Birkir Sveinsson Upotreba cgrp antagonista za lečenje psorijaze
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP2307001A1 (de) * 2008-06-11 2011-04-13 BioChemics, Inc. Kontrolle der blutgefässphysiologie zur behandlung von hauterkrankungen
BRPI0918142A2 (pt) 2008-09-10 2015-12-01 Biochemics Inc composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
WO2010065922A2 (en) 2008-12-04 2010-06-10 Biochemics, Inc. Methods and compositions for tattoo removal
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
IN2012DN02521A (de) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
KR20130018739A (ko) * 2010-03-03 2013-02-25 네오큐티스 에스아 항균 펩티드 격리 화합물을 사용한 피부 질환 및 장애의 치료를 위한 조성물 및 방법
CN106038476B (zh) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
BR112013029932A2 (pt) 2011-05-20 2017-01-31 Alderbio Holdings Llc composições anti-cgrp e usos das mesmas
CA2836800A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP2709662B1 (de) 2011-05-20 2019-07-31 AlderBio Holdings LLC Verwendung von anti-cgrp- oder anti-cgrp-r-antikörpern oder antikörperfragmenten zur behandlung oder prävention chronischer und akuter formen von diarrhöe
KR20200126018A (ko) 2014-03-21 2020-11-05 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
FR3030521B1 (fr) 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
US20180185360A1 (en) * 2015-06-29 2018-07-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye
TW263498B (de) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
SK281575B6 (sk) * 1994-03-21 2001-05-10 Thomsen John Brown Farmaceutický prostriedok vo forme gélu na liečbu kožných ochorení
ATE228834T1 (de) * 1994-09-30 2002-12-15 Oreal Verwendung von einem agonisten eines mit einem chloridkanal assozierten rezeptors zur behandlung von hautfalten
US5445823A (en) * 1994-10-20 1995-08-29 The Procter & Gamble Company Dermatological compositions and method of treatment of skin lesions therewith
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728265A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p dans une composition pharmaceutique
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
PL313515A1 (en) 1996-09-30
CA2172777A1 (fr) 1996-09-29
ATE168011T1 (de) 1998-07-15
HU9600765D0 (en) 1996-05-28
DK0734729T3 (da) 1999-04-19
DK0734729T4 (da) 2004-10-25
RU2152798C1 (ru) 2000-07-20
US6509014B1 (en) 2003-01-21
ES2121461T3 (es) 1998-11-16
US5932215A (en) 1999-08-03
DE69600399T3 (de) 2005-07-14
JPH08268874A (ja) 1996-10-15
EP0734729A1 (de) 1996-10-02
HUP9600765A2 (en) 1997-06-30
FR2732221B1 (fr) 1997-04-25
MX9601150A (es) 1997-02-28
ES2121461T5 (es) 2005-05-01
EP0734729B1 (de) 1998-07-08
HUP9600765A3 (en) 1998-04-28
AR002974A1 (es) 1998-05-27
CA2172777C (fr) 2007-07-24
DE69600399D1 (de) 1998-08-13
FR2732221A1 (fr) 1996-10-04
BR9601478A (pt) 1998-06-02
EP0734729B2 (de) 2004-09-29

Similar Documents

Publication Publication Date Title
DE69600399D1 (de) Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69720463T2 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
ATE229940T1 (de) 3-spiro-indolin-2-onderivate als liganden der vasopressin und/oder der ocytocin rezeptoren
DE69823459D1 (de) Herzbehandlungssystem zur Feststellung und Behandlung von Herzversagen
ATE278400T1 (de) Zusammensetzungen für die verwendung bei der behandlung und prävention von hyperurikämie
ATE205185T1 (de) Benzamid-derivate und deren verwendung als vasopressin-antagonisten
PT914118E (pt) 3,5-difenil-1,2,4-triazoles substituidos e sua utilizacao como quelantes farmaceuticos de metais
DE69600048T2 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE69941266D1 (de) Batchweise behandlung von job-signalen in einem multiverarbeitungssystem
DE69719603D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
DE69622074T2 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
ATE331522T1 (de) Zusammensetzung zur behandlung von atemwegs- und hauterkrankungen mit mindestens einem leukotrienantagonist und mindestens einem antihistaminikum
DE69222258T2 (de) Einrichtung und Verfahren für die Behandlung von Aussenwänden
DE69620270D1 (de) Backfett und dessen Verwendung
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
IT1284499B1 (it) Apparecchiatura di monitoraggio dell'attivita' tettonica
ATE260278T1 (de) 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69841550D1 (de) Behandlung von fibromyalgie und verwandten erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
ATE201828T1 (de) Verwendung eines cgrp antagonisten zur behandlung von flechten und pruritus und so erhaltene zubereitung
ATE205089T1 (de) Verwendung von einem cgrp antagonist für die behandlung von augen oder augenlidpruritus und dysesthesien

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings